P-1251. Pharmacometric Analyses to Support Dose Selection of Zoliflodacin, a First-in-Class Oral Antibiotic Being Developed for the Treatment of Uncomplicated Gonorrhea
Sujata M. Bhavnani(Institute for Clinical Pharmacodynamics (United States)), Christopher M. Rubino(Institute for Clinical Pharmacodynamics (United States)), John P. O’Donnell(Entasis Therapeutics (United States)), Alison Luckey(Global Antibiotic Research & Development Partnership), Pierre Daram(Global Antibiotic Research & Development Partnership), Anthony P Cammarata(Institute for Clinical Pharmacodynamics (United States)), Jeffrey Hammel(Institute for Clinical Pharmacodynamics (United States)), Kajal Larson(Entasis Therapeutics (United States))
Cited by 4
Related Papers
The Impact of Morbid Obesity, Pneumoperitoneum, and Posture on Respiratory System Mechanics and Oxygenation During Laparoscopy
|Anesthesia & Analgesia|2002|198
Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study
|Journal of Antimicrobial Chemotherapy|2019|123
Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
|The Lancet Infectious Diseases|2024|98
Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia
|Journal of Antimicrobial Chemotherapy|2020|67
Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance
|International Journal of Antimicrobial Agents|2021|34